Save time and jump to the most important pieces.
3 - Orgenesis Inc. (0001460602) (Issuer)
3 - Orgenesis Inc. (0001460602) (Issuer)
3 - Orgenesis Inc. (0001460602) (Issuer)
10-Q - Orgenesis Inc. (0001460602) (Filer)
8-K - Orgenesis Inc. (0001460602) (Filer)
8-K - Orgenesis Inc. (0001460602) (Filer)
GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners ("Metalmark"), for the acquisition of its approximate 25% stake in Octomera LLC ("Octomera"), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027,
Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, "We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Servic
GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl
Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc
GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C
SC 13G/A - Orgenesis Inc. (0001460602) (Subject)
SC 13G/A - Orgenesis Inc. (0001460602) (Subject)
SC 13G - Orgenesis Inc. (0001460602) (Subject)
GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the
GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic
New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here - Alpine 4 Technologies Inc (OTCQB:ALPP) say
4 - Orgenesis Inc. (0001460602) (Issuer)
4 - Orgenesis Inc. (0001460602) (Issuer)
- SEC Filing
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering. Kaival Brands priced its 3,921,500 unit offering at $15.3 per unit. Kaival Brands Innovations Group shares dipped 47% to $1.52 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers American Rebel Holdings, Inc. (NASDAQ:AREB) shares jumped 161% to $0.8048 after the company signed a Connecticut distribution agreement with Dichello Distributors. Sharecare, Inc. (NASDAQ:SHCR) jumped 74% to $1.35 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.